Table 3.
Resource utilization per client, by model and study period (mean per client per annum, total cohort)
| Service/item (Mean frequency per client/annum) |
FBIM (n = 128) |
CCLAD (n = 131) |
CDDP (n = 132) |
FBG1/2 (n = 129, 115)a |
FDR (n = 133) |
Total (n = 653) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Months 0–12 | ||||||||||||||||||
| Laboratory investigations | ||||||||||||||||||
| Viral load testsb (mean number per client) | 1.05 | 1.15 | 1.18 | 1.09 | 1.02 | 1.09 | ||||||||||||
| Clients with unrecorded viral status | 6 (5%) | 2 (2%) | 1 (1%) | 8 (6%) | 11 (9%) | 28 (4.3%) | ||||||||||||
| All other (non-VL) tests | 0.38 | 0.84 | 0.24 | 1.19 | 0.44 | 0.62 | ||||||||||||
| Facility visits / DSDM events | ||||||||||||||||||
| Mean duration of dispensing interval (months) | 1.6 | 1.9 | 1.7 | 1.6 | 2.0 | 1.7 | ||||||||||||
| Facility visitsc | 7.74 | 6.44 | 6.91 | 7.57 | 6.12 | 6.95 | ||||||||||||
| DSDM eventsd | 0.00 | 3.60 | 4.16 | 6.12e | 0.00 | 2.77 | ||||||||||||
| Total interactions | 7.74 | 10.04 | 11.07 | 13.69 | 6.12 | 9.72 | ||||||||||||
| Months 13–24 | ||||||||||||||||||
| Laboratory investigations | ||||||||||||||||||
| Viral load testsb (mean number per client) | 0.98 | 0.83 | 0.92 | 1.15 | 0.92 | 0.95 | ||||||||||||
| Clients with unrecorded viral status | 5 (4%) | 11 (9%) | 8 (7%) | 3 (3%) | 10 (8%) | 37 (6%) | ||||||||||||
| All other (non-VL) tests | 0.29 | 0.42 | 0.05 | 0.54 | 0.15 | 0.28 | ||||||||||||
| Facility visits / DSDM events | ||||||||||||||||||
| Mean duration of dispensing interval (months) | 1.6 | 2.0 | 2.0 | 1.3 | 2.1 | 1.8 | ||||||||||||
| Facility visitsc | 7.63 | 5.92 | 6.07 | 9.05 | 5.82 | 6.84 | ||||||||||||
| DSDM eventsd | 0.00 | 2.00 | 1.92 | 6.6 e | 0.00 | 2.01 | ||||||||||||
| Total interactions | 7.63 | 7.92 | 7.99 | 15.70 | 5.82 | 8.85 | ||||||||||||
a Months 0–12 are FBG1 data. Months 13–24 are FBG2 data
b Viral load test frequency is guided by the MOH Treatment Guidelines. Other tests are done if clinically indicated
c Facility visits could be either scheduled ARV collections or unscheduled visits for other needs. Included ARV collections for all DSDM clients, even if collected by a community/group member on behalf of the client – and costs of pharmacy and nurse time were split between group members
d DSDM events count excluded the ARV pickups from facilities which were counted as facility visits
e FBG support groups could occur in community or at facilities, but are all labelled here as DSDM events